BeiGene (06160) announced first-half results, adjusted net profit of about US$819.5 million, an increase of 111% year-on-year

According to the Zhitong Finance App, BeiGene (06160) announced results for the second quarter of 2026, with total global revenue of about US$1.705 billion, up 30% year on year; GAAP net profit of about US$237 million, up 151% year on year; adjusted net profit of about US$444 million, up 76% year on year.

Among them, product revenue for the second quarter of 2026 was US$1.7 billion, an increase of 29% over the previous year. Global sales of Baiyuze® in the second quarter were US$1.2 billion, up 31% year over year; of these, in the US market, PARK® sales were US$893 million, up 31% year over year. Global sales of Baizean® (tirelizumab) in the second quarter were US$229 million, an increase of 18% over the previous year. Global sales of Amgen's licensed products in the second quarter were US$157 million, up 25% year over year.

In the first half of 2026, total revenue was US$3,218.5 million, up 32% year on year; GAAP net profit was about US$464 million, up 386% year on year; adjusted net profit was approximately US$819.5 million, up 111% year on year.

Mr. Ou Leiqiang, co-founder, chairman and CEO of BeiGene, said, “The strong results in the second quarter once again confirm the company's continued growth as a global leader in oncology treatment. The core hematologic oncology business, represented by Baiyueze®, continues to maintain strong momentum, and we are continuing to advance one of the most diverse and deep R&D pipelines in the industry. With our differentiated capabilities covering drug discovery, clinical development, production, and commercialization, we are fully prepared for the next phase of global growth.”

Additionally, BeiGene's total revenue guidance for the full year 2026 is between $6.6 billion and $6.8 billion, including strong growth expectations from the leading position in the US market and continued expansion in other important European and global markets. The gross margin is expected to be high in the 80% range, including the impact of the product portfolio and increased production efficiency throughout 2026. The company's guidance on GAAP operating expenses includes anticipated investments to support future growth. GAAP operating profit of USD 1 billion to USD 1.1 billion, and non-GAAP operating profit of USD 1.7 billion to USD 1.8 billion